CR20210221A - Derivados de azitromicina y roxitromicina como fármacos senolíticos - Google Patents
Derivados de azitromicina y roxitromicina como fármacos senolíticosInfo
- Publication number
- CR20210221A CR20210221A CR20210221A CR20210221A CR20210221A CR 20210221 A CR20210221 A CR 20210221A CR 20210221 A CR20210221 A CR 20210221A CR 20210221 A CR20210221 A CR 20210221A CR 20210221 A CR20210221 A CR 20210221A
- Authority
- CR
- Costa Rica
- Prior art keywords
- azithromycin
- senolytic
- roxithromycin
- activity
- showed
- Prior art date
Links
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 title 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title 1
- 229960004099 azithromycin Drugs 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000009327 senolytic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta descripción expone el uso de azitromicina,roxitromicina y teli tromicina, inclusive derivados de los mismos,como fármacos senolíticos. La BrdU se usó para inducir la senescencia en un modelo de líneas de células fibroblastos humanas. También se dan a conocer métodos para seleccionar compuestos por la actividad senolítica. El ensayo de SRB se usó para medir la viabilidad celular a través del contenido de proteínas. Se descubrió que la azitromicina, la roxitromicina y latelitromicina, productos farmacéuticos aprobados clínicamente, son fármacos senolíticos. Sin embargo, el compuesto precursor relacionado estrechamente, eritromicina, no mostró actividad senolítica. La azitromicina indujo considerablemente tanto glicólisis aeróbica como autofagia en fibroblastos humanos, pero mostró efectos bifásicos que incluían sobre las tasas de consumo de oxígeno mitocondrial con actividad inhibitoria a 50 µM y actividad estimuladora a 100 µM. El sistema de ensayo en tiempo real xCELLigenceMR mostró que la azitromicina focaliza preferentemente las células senescentes, eliminando aproximadamente 97% (casi una reducción de 25 veces en las células senescentes).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740137P | 2018-10-02 | 2018-10-02 | |
| US201862750559P | 2018-10-25 | 2018-10-25 | |
| US201962788187P | 2019-01-04 | 2019-01-04 | |
| PCT/US2019/054231 WO2020072598A1 (en) | 2018-10-02 | 2019-10-02 | Azithromycin and roxithromycin derivatives as senolytic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210221A true CR20210221A (es) | 2021-06-24 |
Family
ID=70054763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210221A CR20210221A (es) | 2018-10-02 | 2019-10-02 | Derivados de azitromicina y roxitromicina como fármacos senolíticos |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11957700B2 (es) |
| EP (1) | EP3860616B1 (es) |
| JP (1) | JP7538119B2 (es) |
| KR (1) | KR20210072026A (es) |
| CN (1) | CN113164504B (es) |
| AU (1) | AU2019353002B2 (es) |
| BR (1) | BR112021006423A2 (es) |
| CA (1) | CA3114888A1 (es) |
| CL (1) | CL2021000825A1 (es) |
| CO (1) | CO2021004427A2 (es) |
| CR (1) | CR20210221A (es) |
| CU (1) | CU24717B1 (es) |
| DO (1) | DOP2021000056A (es) |
| EC (1) | ECSP21029576A (es) |
| IL (1) | IL281879B2 (es) |
| MX (1) | MX2021003808A (es) |
| PE (1) | PE20211006A1 (es) |
| PH (1) | PH12021550719A1 (es) |
| SG (1) | SG11202103293UA (es) |
| WO (1) | WO2020072598A1 (es) |
| ZA (1) | ZA202102157B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20200238A (es) * | 2017-11-24 | 2020-12-04 | Lunella Biotech Inc | Compuestos derivados de trifenilfosfonio para erradicar células madre cancerosas |
| CA3123850A1 (en) * | 2018-12-17 | 2020-06-25 | Lunella Biotech, Inc. | Triple combination therapies for anti-aging |
| GB202014160D0 (en) * | 2020-09-09 | 2020-10-21 | Nuchido Ltd | Senolytic compounds and compositions |
| KR102673862B1 (ko) * | 2021-07-27 | 2024-06-10 | 전남대학교 산학협력단 | Sestrin2를 유전자가 삽입된 재조합 레트로바이러스 벡터를 포함하는 골 질환 예방 또는 치료용 약제학적 조성물 |
| US20250108036A1 (en) * | 2021-11-10 | 2025-04-03 | Lifeceutix Co., Ltd. | Compositions for removing senescent cells and uses thereof |
| WO2023090901A1 (ko) * | 2021-11-18 | 2023-05-25 | 의료법인 성광의료재단 | 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법 |
| IL328715A (en) * | 2023-11-30 | 2026-07-01 | Lunella Biotech Inc | Senolytic preparations |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20022292A1 (it) * | 2002-10-29 | 2004-04-30 | Zambon Spa | 9a-azalidi ad attivita' antiinfiammatoria. |
| EP2716647A3 (en) | 2004-02-27 | 2014-08-20 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
| PL2102226T3 (pl) * | 2006-12-12 | 2013-01-31 | Zambon Spa | Związki makrolidowe o aktywności przeciwzapalnej |
| GB0912584D0 (en) * | 2009-07-20 | 2009-08-26 | Ucl Business Plc | Cyclosporin conjugates |
| US9180134B2 (en) * | 2011-08-18 | 2015-11-10 | Ecole Polytechnique Federale De Lausanne (Epel) | Mitochondrial ribosomal proteins as aging regulators |
| WO2013040206A1 (en) | 2011-09-14 | 2013-03-21 | Lewis Thomas J | Novel formulations comprising macrolide and tetracycline and their uses |
| KR101435717B1 (ko) * | 2012-09-06 | 2014-09-01 | 영남대학교 산학협력단 | 퀘세틴-3-Ｏ-β-Ｄ-글루쿠로니드를 유효성분으로 함유하는 세포 노화 억제용 조성물 |
| US20180021323A1 (en) * | 2015-01-22 | 2018-01-25 | Bioventures, Llc | Flip - a selective molecular target of senescent cells |
| JP7790686B2 (ja) | 2017-01-03 | 2025-12-23 | バイオアトラ インコーポレイテッド | 老化細胞の処置のためのタンパク質療法 |
| EP3596043B1 (en) | 2017-03-15 | 2025-12-03 | Lunella Biotech, Inc. | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast |
| US11427606B2 (en) * | 2017-04-20 | 2022-08-30 | Rising Tide Foundation | Azithromycin derivatives containing a phosphonium ion as anticancer agents |
| CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| JP6938682B2 (ja) | 2017-05-19 | 2021-09-22 | ルネラ・バイオテック・インコーポレーテッド | アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬 |
| US12006553B2 (en) | 2017-05-19 | 2024-06-11 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| CU20190106A7 (es) | 2017-06-26 | 2020-11-30 | Lunella Biotech Inc | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas |
| WO2019083997A1 (en) | 2017-10-24 | 2019-05-02 | Lunella Biotech, Inc. | MITOFLAVOSCINS: TARGETING FLAVIN-CONTAINING ENZYMES THAT REMOVE CANCER STEM CELLS (CSC) BY INHIBITING MITOCHONDRIAL BREATHING |
| CR20200238A (es) | 2017-11-24 | 2020-12-04 | Lunella Biotech Inc | Compuestos derivados de trifenilfosfonio para erradicar células madre cancerosas |
| CA3083487A1 (en) | 2017-12-01 | 2019-06-06 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| US11559527B2 (en) | 2017-12-20 | 2023-01-24 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mDIVI-1 derivatives |
| CA3123850A1 (en) | 2018-12-17 | 2020-06-25 | Lunella Biotech, Inc. | Triple combination therapies for anti-aging |
-
2019
- 2019-10-02 CU CU2021000024A patent/CU24717B1/es unknown
- 2019-10-02 IL IL281879A patent/IL281879B2/en unknown
- 2019-10-02 CR CR20210221A patent/CR20210221A/es unknown
- 2019-10-02 CA CA3114888A patent/CA3114888A1/en active Pending
- 2019-10-02 WO PCT/US2019/054231 patent/WO2020072598A1/en not_active Ceased
- 2019-10-02 EP EP19869744.3A patent/EP3860616B1/en active Active
- 2019-10-02 MX MX2021003808A patent/MX2021003808A/es unknown
- 2019-10-02 BR BR112021006423A patent/BR112021006423A2/pt unknown
- 2019-10-02 KR KR1020217012994A patent/KR20210072026A/ko not_active Ceased
- 2019-10-02 US US17/282,212 patent/US11957700B2/en active Active
- 2019-10-02 PE PE2021000425A patent/PE20211006A1/es unknown
- 2019-10-02 AU AU2019353002A patent/AU2019353002B2/en active Active
- 2019-10-02 JP JP2021518508A patent/JP7538119B2/ja active Active
- 2019-10-02 SG SG11202103293UA patent/SG11202103293UA/en unknown
- 2019-10-02 CN CN201980079188.4A patent/CN113164504B/zh active Active
-
2021
- 2021-03-30 ZA ZA2021/02157A patent/ZA202102157B/en unknown
- 2021-03-31 DO DO2021000056A patent/DOP2021000056A/es unknown
- 2021-03-31 CL CL2021000825A patent/CL2021000825A1/es unknown
- 2021-03-31 PH PH12021550719A patent/PH12021550719A1/en unknown
- 2021-04-09 CO CONC2021/0004427A patent/CO2021004427A2/es unknown
- 2021-04-26 EC ECSENADI202129576A patent/ECSP21029576A/es unknown
-
2024
- 2024-02-15 US US18/442,204 patent/US12208111B2/en active Active
- 2024-12-19 US US18/987,745 patent/US20250120994A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202102157B (en) | 2022-09-28 |
| US20240180944A1 (en) | 2024-06-06 |
| CO2021004427A2 (es) | 2021-04-30 |
| KR20210072026A (ko) | 2021-06-16 |
| US20210275560A1 (en) | 2021-09-09 |
| EP3860616B1 (en) | 2024-08-21 |
| AU2019353002B2 (en) | 2024-11-14 |
| CU20210024A7 (es) | 2021-11-04 |
| IL281879B2 (en) | 2026-04-01 |
| EP3860616A1 (en) | 2021-08-11 |
| CL2021000825A1 (es) | 2021-10-22 |
| CA3114888A1 (en) | 2020-04-09 |
| IL281879B1 (en) | 2025-12-01 |
| ECSP21029576A (es) | 2021-05-31 |
| WO2020072598A1 (en) | 2020-04-09 |
| US11957700B2 (en) | 2024-04-16 |
| MX2021003808A (es) | 2021-05-27 |
| PE20211006A1 (es) | 2021-06-01 |
| DOP2021000056A (es) | 2021-06-30 |
| EP3860616A4 (en) | 2022-07-06 |
| CN113164504A (zh) | 2021-07-23 |
| IL281879A (en) | 2021-05-31 |
| BR112021006423A2 (pt) | 2021-07-06 |
| PH12021550719A1 (en) | 2021-12-06 |
| US12208111B2 (en) | 2025-01-28 |
| AU2019353002A1 (en) | 2021-05-06 |
| US20250120994A1 (en) | 2025-04-17 |
| SG11202103293UA (en) | 2021-04-29 |
| JP2022504204A (ja) | 2022-01-13 |
| JP7538119B2 (ja) | 2024-08-21 |
| CN113164504B (zh) | 2024-12-13 |
| CU24717B1 (es) | 2024-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003808A (es) | Derivados de azitromicina y roxitromicina como farmacos senoliticos. | |
| Meca et al. | Comparative cytotoxicity study of enniatins A, A1, A2, B, B1, B4 and J3 on Caco-2 cells, Hep-G2 and HT-29 | |
| Long et al. | Discovery of the signal pathways and major bioactive compounds responsible for the anti-hypoxia effect of Chinese cordyceps | |
| Zou et al. | Cordyceps sinensis oral liquid prolongs the lifespan of the fruit fly, Drosophila melanogaster, by inhibiting oxidative stress | |
| Nelson et al. | VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENTNAïVE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS: LB-14 | |
| WO2008080153A3 (en) | A novel protein kinase c therapy for the treatment of acute lung injury | |
| MXPA05011435A (es) | 5-hidroxiindoles con grupos de n-oxido y su uso como inhibidores de fosfodiesterasa 4. | |
| Sadovnikov et al. | Synthetic peptide octarphin (TPLVTLFK), a selective agonist of nonopioid β‐endorphin receptor, stimulates nitric oxide synthesis in macrophages | |
| BRPI0409790A (pt) | 7-azaindóis e seu uso como terapêuticos | |
| Ribeiro | Chemoreceptors in respiratory control | |
| 김민주 et al. | Mitochondrial Complexes I and II Are More Susceptible to Autophagy Deficiency in Mouse β-Cells Min Joo | |
| MUSTAFA et al. | 10.16. Effect of Aprotinin on Levels of Adenine | |
| 李溱 | Comprehensive Review on “Critical Period Hypothesis” and the Role of Age in Second Language Learning | |
| De Abreu et al. | Synergy of Methotrexate and 6-Mercaptopurine on Cell Growth and Clono-Genicity of Cultured Human T-Lymphoblasts | |
| Tatler et al. | B56 SCAR WARS: INSIGHTS INTO MECHANISMS AND TREATMENTS OF PULMONARY FIBROSIS: Caffeine Inhibits Tgfâ Activation In Lung Epithelial Cells And Reduces Pulmonary Fibrosis In Ex Vivo Precision-Cut Lung Slices | |
| Thirugnanam et al. | Sucrose non-fermenting related kinase regulates cardiomyocyte protection during cardiac stress | |
| Takizawa et al. | Direct Sensing of Lipopolysaccharide Limits Hematopoietic Stem Cell Selfrenewal Via TLR4-TRIF-ROS-p38 Pathway | |
| 刘航 | Effect and mechanism of cysteine-rich protein 61 on transforming growth factor-β1-activatedrenal fibroblasts | |
| Kolesnichenko et al. | Potentiating interaction of ethoxydol and rosuvastatin in an experimental model of langendorf-isolated rat heart total ischemia-reperfusion | |
| Jia et al. | Effects of estrogen on the expression of phosphofructokinase muscle-specific isoform in genioglossus of chronic intermittent hypoxia rats | |
| Nelson et al. | Genome-Wide Association Study to Characterize Potential Determinants of Bilirubin Elevations in HCV Patients Receiving the HCV NS3 Serine Protease Inhibitor GS-9256: 806 | |
| SUN et al. | Investigation of the expression and DNA binding activity of signal transducer and activator of tran-scription 5 after interleukin 2 therapy for recurrent genital herpes | |
| Jin-Ru et al. | Effects of lead exposure on acid-sensing ion channel in hippocampus of baby-rats | |
| Audrey | Egypt Aiming at Attracting Investment from China | |
| 赵明 et al. | Protective Effect of Lithium Chloride on MPTP and Rotenone-Treated PC12 Cell |